KR20210065962A - 혈액학적 장애의 저강도 치료 - Google Patents

혈액학적 장애의 저강도 치료 Download PDF

Info

Publication number
KR20210065962A
KR20210065962A KR1020217011132A KR20217011132A KR20210065962A KR 20210065962 A KR20210065962 A KR 20210065962A KR 1020217011132 A KR1020217011132 A KR 1020217011132A KR 20217011132 A KR20217011132 A KR 20217011132A KR 20210065962 A KR20210065962 A KR 20210065962A
Authority
KR
South Korea
Prior art keywords
composition
cpx
treatment
cytarabine
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217011132A
Other languages
English (en)
Korean (ko)
Inventor
치 왕
로날드 청
스테판 파데를
Original Assignee
셀라토 파마슈티칼즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀라토 파마슈티칼즈, 인코포레이티드 filed Critical 셀라토 파마슈티칼즈, 인코포레이티드
Publication of KR20210065962A publication Critical patent/KR20210065962A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217011132A 2018-09-25 2019-09-25 혈액학적 장애의 저강도 치료 Ceased KR20210065962A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862736393P 2018-09-25 2018-09-25
US62/736,393 2018-09-25
US201862772372P 2018-11-28 2018-11-28
US62/772,372 2018-11-28
PCT/US2019/052952 WO2020068979A1 (en) 2018-09-25 2019-09-25 Low-intensity treatment of hematological disorders

Publications (1)

Publication Number Publication Date
KR20210065962A true KR20210065962A (ko) 2021-06-04

Family

ID=69950910

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217011132A Ceased KR20210065962A (ko) 2018-09-25 2019-09-25 혈액학적 장애의 저강도 치료

Country Status (11)

Country Link
US (3) US20240252522A1 (https=)
EP (1) EP3856198A4 (https=)
JP (1) JP2022502498A (https=)
KR (1) KR20210065962A (https=)
CN (1) CN113164502A (https=)
AU (1) AU2019350759A1 (https=)
BR (1) BR112021005539A2 (https=)
CA (1) CA3114002A1 (https=)
IL (1) IL281729A (https=)
MX (1) MX2021003527A (https=)
WO (1) WO2020068979A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108778260A (zh) * 2015-11-11 2018-11-09 塞拉特药物股份有限公司 选择白血病对象的治疗方案的分析和方法
EP3856198A4 (en) * 2018-09-25 2022-06-22 Celator Pharmaceuticals, Inc. Low-intensity treatment of hematological disorders
EP4333822A1 (en) 2021-05-03 2024-03-13 Lead Discovery Center GmbH Composition comprising an inhibitor of mitochondrial transcription

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2462376C (en) 2001-10-03 2010-12-14 Celator Technologies Inc. Liposome loading with metal ions
CA2467064C (en) 2001-11-13 2011-02-08 Murray Webb Lipid carrier compositions with enhanced blood stability
WO2005102359A1 (en) 2004-04-22 2005-11-03 Celator Pharmaceuticals, Inc. Liposomal formulations of anthracycline agents and cytidine analogs
EP4046640A1 (en) * 2007-02-16 2022-08-24 Rotalec IP Holdings LLC Fixed drug ratios of cytarabine to daunorubicin for treatment of hematopoietic cancers and proliferative disorders
EP3572071A1 (en) 2011-10-21 2019-11-27 Jazz Pharmaceuticals Research LLC Lyophilized liposomes
CN108778260A (zh) * 2015-11-11 2018-11-09 塞拉特药物股份有限公司 选择白血病对象的治疗方案的分析和方法
BR112019001570A2 (pt) * 2016-07-28 2019-07-09 Novartis Ag terapias de combinação de receptores de antígeno quiméricos e inibidores de pd-1
WO2018101214A1 (ja) 2016-12-01 2018-06-07 Ｊｘｔｇエネルギー株式会社 全芳香族液晶ポリエステル樹脂
EP3856198A4 (en) * 2018-09-25 2022-06-22 Celator Pharmaceuticals, Inc. Low-intensity treatment of hematological disorders
US11980636B2 (en) * 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders

Also Published As

Publication number Publication date
US20210393665A1 (en) 2021-12-23
US20240252522A1 (en) 2024-08-01
EP3856198A1 (en) 2021-08-04
BR112021005539A2 (pt) 2021-06-29
CN113164502A (zh) 2021-07-23
EP3856198A4 (en) 2022-06-22
CA3114002A1 (en) 2020-04-02
US12370207B2 (en) 2025-07-29
JP2022502498A (ja) 2022-01-11
MX2021003527A (es) 2021-05-27
AU2019350759A1 (en) 2021-04-22
IL281729A (en) 2021-05-31
US20260014183A1 (en) 2026-01-15
WO2020068979A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
US20260014183A1 (en) Low-intensity treatment of hematological disorders
JP2022009657A (ja) リポソーム型イリノテカン及びオキサリプラチンを含む組み合わせ療法を使用して転移性膵臓癌を治療するための方法
CA2890111A1 (en) Tec family kinase inhibitor adjuvant therapy
JP2011505336A (ja) 骨髄異形成症候群治療のためのシチジンアナログ
Nogueira-Rodrigues et al. Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer
JP2017071625A (ja) 抗癌療法
WO2021217038A1 (en) SIRPα DEFICIENT MACROPHAGES FOR TREATING CANCER
Reinius et al. Anti-cancer therapy with cyclin-dependent kinase inhibitors: Impact and challenges
JP2016501208A (ja) ボラセルチブとの併用療法
JP2025507017A (ja) 胃がんにおける抗ヒトｃｄ３９抗体、抗ヒトｐｄ－１抗体、及び化学療法による併用
US20240252526A1 (en) Treatment of hematological disorders
AU2020326612B2 (en) Treatment of canine cancers
CN121622884A (zh) 包含间充质干细胞制剂与免疫检查点抑制剂的肿瘤治疗组合物、试剂盒及其用途
Smith et al. Differentiation therapy in poor risk myeloid malignancies: results of a dose finding study of the combination bryostatin-1 and GM-CSF
WO2025076500A1 (en) Cancer treatments using mta-cooperative prmt5 inhibitors
KR20160037233A (ko) 급성 골수성 백혈병 및 골수형성이상 증후군의 치료를 위한 데시타빈과 병용된 볼라세르티브
TWI867142B (zh) 一種用於緩解癌症化療引起抗藥性並對化療增效之醫藥組合物及其用途
WO2021156340A1 (en) Pdac treatment regimen
KR20160035067A (ko) 급성 골수성 백혈병 및 골수형성이상 증후군의 치료를 위한 아자시티딘과 병용된 볼라세르티브
US12472227B2 (en) Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy
JP2009509974A (ja) 抗癌治療
HK40087074A (zh) 用於治疗癌症的缺乏SIRPα的巨噬细胞
AU2024294949A1 (en) Treatment of acute myeloid leukemia with olutasidenib, venetoclax and a hypomethylating agent
KR20210097139A (ko) 데비미스타트를 사용하는 급성 골수성 백혈병을 치료하기 위한 치료적 방법 및 조성물
HK40092504A (zh) 治疗癌症的bcl-2抑制剂和低甲基化剂的组合、其用途和药物组合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000